This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
by Zacks Equity Research
BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.
SNYPositive Net Change BMRNPositive Net Change FOLDPositive Net Change HRMYNegative Net Change
biotechs earnings
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
by Zacks Equity Research
Summit Therapeutics posts a wider Q4 loss as R&D spending surges. Its ivonescimab pipeline advances with a BLA filing and multiple late-stage cancer trials underway.
GSKPositive Net Change MRKPositive Net Change SMMTPositive Net Change ASRTNegative Net Change
biotechs
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
by Sundeep Ganoria
With Amtagvi sales surging but shares down 46%, can Iovance's growth runway outshine Rigel's strong 2025 rally?
SNYPositive Net Change LLYPositive Net Change RIGLNegative Net Change IOVAPositive Net Change
biotechs medical pharmaceuticals
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
TBPHPositive Net Change CRMDNegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
by Zacks Equity Research
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
BMRNPositive Net Change FOLDPositive Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechs earnings
FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug
by Zacks Equity Research
FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.
RHHBYPositive Net Change ASRTNegative Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechs
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
by Kanishka Das
CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.
PFEPositive Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechs
Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?
by Sundeep Ganoria
ANIP gears up for Q4 earnings as Cortrophin Gel sales are expected to have surged, with rare disease momentum building despite generic competition pressures.
REGNPositive Net Change ABBVPositive Net Change ANIPNegative Net Change
biotechs earnings-preview medical
What's in Store for These 5 Medical Companies This Earnings Season?
by Ahan Chakraborty
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
IRWDNegative Net Change NVAXNegative Net Change NTLANegative Net Change VTRSNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Stock to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
VTRS gears up for Q4 results amid Indore import alert, segment revenue pressure and steady margins as shares surge 39.7% in a year.
AMRXNegative Net Change CSTLNegative Net Change VTRSNegative Net Change TERNPositive Net Change
biotechnology biotechs medical pharmaceuticals